［1］Benevolo G，Stacchini A，Spina M，et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination［J］. Blood，2012，120（16）：3222-3228. doi：10.1182/blood-2012-04-423095.

［2］Swerdlow SH，Campo E，Pileri SA，et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms［J］. Blood，2016，127（20）：2375-2390. doi：10.1182/blood-2016-01-643569.

［3］Lenz G，Wright GW，Emre NC，et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways［J］. Proc Natl Acad Sci USA，2008，105（36）：13520-13525. doi：10.1073/pnas.0804295105.

［4］Scott DW，Wright GW，Williams PM，et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue［J］. Blood，2014，123（8）：1214-1217. doi：10.1182/blood-2013-11-536433.

［5］Wright G，Tan B，Rosenwald A，et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma［J］. Proc Natl Acad Sci USA，2003，100（17）：9991-9996. doi：10.1073/pnas.1732008100.

［6］Savage KJ，Johnson NA，Ben-Neriah S，et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy［J］. Blood，2009，114（17）：3533-3537. doi：10.1182/blood-2009-05-220095.

［7］Barrans S，Crouch S，Smith A，et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab［J］. Journal of clinical oncology ：official journal of the American Society of Clinical Oncology，2010，28（20）：3360-3365.doi：10.1200/jco.2009.26.3947.

［8］Lin P，Dickason TJ，Fayad LE，et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma，unclassifiable，with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma［J］. Cancer，2012，118（6）：1566-1573. doi：10.1002/cncr.26433.

［9］Green TM，Young KH，Visco C，et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide，doxorubicin，vincristine，and prednisone［J］. Journal of clinical oncology ：official journal of the American Society of Clinical Oncology，2012，30（28）：3460-3467. doi：10.1200/jco.2011.41.4342.

［10］Johnson NA，Slack GW，Savage KJ，et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide，doxorubicin，vincristine，and prednisone［J］. Journal of clinical oncology ：official journal of the American Society of Clinical Oncology，2012，30（28）：3452-3459. doi：10.1200/jco.2011.41.0985.

［11］Horn H，Ziepert M，Becher C，et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma［J］.Blood，2013，121（12）：2253-2263.doi：10.1182/blood-2012-06-435842.

［12］Xue K，Gu JJ，Zhang Q，et al. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma：Results from a randomized prospective clinical trial［J］. Oncotarget，2016，7（22）：32519-32531. doi：10.18632/oncotarget.8685.

［13］Cai QC，Gao Y，Wang XX，et al. Long-term results of the R-CEOP90 in the treatment of young patients with chemotherapy-naive diffuse large B cell lymphoma：a phase Ⅱ study［J］. Leukemia &lymphoma，2014，55（10）：2387-2388. doi：10.3109/10428194.2013.876632.

［14］Held G，Murawski N，Ziepert M，et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma［J］. Journal of clinical oncology ：official journal of the American Society of Clinical Oncology，2014，32（11）：1112-1118. doi：10.1200/jco.2013.51.4505.

［15］Pfreundschuh M，Kuhnt E，Trumper L，et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diff use large-B-cell lymphoma：6-year results of an open-label randomised study of the MabThera International Trial （MInT） Group［J］.The Lancet Oncology，2011，12（11）：1013-1022.doi：10.1016/s1470-2045（11）70235-2.

［16］Stephens DM，Li H，LeBlanc ML，et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma：final and long-term analysis of Southwest Oncology Group Study S8736［J］. Journal of clinical oncology ：official journal of the American Society of Clinical Oncology，2016，34（25）：2997-3004. doi：10.1200/JCO.2015.65.4582.

［17］Vargo JA，Gill BS，Balasubramani GK，et al. Treatment selection and survival outcomes in early(-?)stage diffuse large B-cell lymphoma：do we still need consolidative radiotherapy?［J］. Journal of clinical oncology ：official journal of the American Society of Clinical Oncology，2015. doi：10.1200/JCO.2015.61.7654.

［18］Cunningham D，Hawkes EA，Jack A，et al. Rituximab plus cyclophosphamide，doxorubicin，vincristine，and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma：a phase 3 comparison of dose intensification with 14-day versus 21-day cycles［J］.Lancet，2013，381（9880）：1817-1826. doi：10.1016/s0140-6736（13）60313-x.

［19］Dunleavy K，Pittaluga S，Maeda LS，et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma［J］. The New England journal of medicine，2013，368（15）：1408-1416. doi：10.1056/NEJMoa1214561.

［20］Morris PG，Correa DD，Yahalom J，et al. Rituximab，methotrexate，procarbazine，and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma：final results and long-term outcome［J］. Journal of clinical oncology ：official journal of the American Society of Clinical Oncology，2013，31（31）：3971-3979. doi：10.1200/JCO.2013.50.4910.

［21］Thiel E，Korfel A，Martus P，et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma （G-PCNSL-SG-1）：a phase 3，randomised，non-inferiority trial［J］.The Lancet Oncology，2010，11（11）：1036-1047. doi：10.1016/S1470-2045（10）70229-1.

［22］Schmitz N，Zeynalova S，Nickelsen M，et al. CNS international prognostic index：a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP［J］. Journal of clinical oncology ：official journal of the American Society of Clinical Oncology，2016，34（26）：3150-3156. doi：10.1200/jco.2015.65.6520.

［23］Hagberg H，Gisselbrecht C，CORAL study group. Randomised phase Ⅲ study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma （DLBCL） followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not：an update of the CORAL study. Ann Oncol，2006 May，17 Suppl 4：iv31-32.

［24］Shen QD，Zhu HY，Wang L，et al. Gemcitabine-oxaliplatin plus rituximab （R-GemOx） as first(-?)line treatment in elderly patients with diffuse large B-cell lymphoma：a single-arm，open-label，phase 2 trial. Lancet Haematol，2018 Jun，5（6）：e261-e269. doi：10.1016/S2352-3026（18）30054-1.

［25］Crump M，Kuruvilla J，Couban S，et al. Randomized comparison of gemcitabine，dexamethasone，and cisplatin versus dexamethasone，cytarabine，and cisplatin chemotherapy before autologous stem(-?)cell transplantation for relapsed and refractory aggressive lymphomas：NCIC-CTG LY.12. J Clin Oncol，2014 Nov 1；32（31）：3490-3496. doi：10.1200/JCO.2013.53.9593.

［26］Rodriguez MA，Cabanillas FC，Velasquez W，et al. Results of a salvage treatment program for relapsing lymphoma：MINE consolidated with ESHAP. J Clin Oncol，1995 Jul，13（7）：1734-1741.

［27］Wiernik PH，Lossos IS，Tuscano JM，et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol，2008 Oct 20，26（30）：4952-4957. doi：10.1200/JCO.2007.15.3429.

［28］Witzig TE，Vose JM，Zinzani PL，et al. An international phase Ⅱ trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol，2011 Jul，22（7）：1622-1627. doi：10.1093/annonc/mdq626.

［29］Wang M，Fowler N，Wagner-Bartak N，et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell，follicular and transformed lymphoma：a phase Ⅱ clinical trial. Leukemia，2013 Sep，27（9）：1902-1909. doi：10.1038/leu.2013.95.